AIM ImmunoTech Inc. (AIM) 股票分析

公司概述

AIM ImmunoTech Inc. operates as an immuno-pharma entity dedicated to the research and development of therapeutic agents designed to address multiple forms of cancer, viral diseases, and immune-deficiency disorders within the United States market. The company functions within the healthcare sector, specifically targeting the biotechnology industry, a domain characterized by high innovation cycles and significant regulatory hurdles. In terms of scale, AIM ImmunoTech Inc. carries a market capitalization of $4.22M, generated $88,000 in annual revenue over the trailing twelve months, and maintains a workforce of 19 employees. These valuation and revenue figures indicate that the company occupies a micro-cap position with very limited commercial scale, reflecting a stage where product development costs substantially outweigh current sales revenue.

财务健康

The company reported a trailing twelve-month revenue of $88,000 paired with a net income of $-13,958,000, while its EBITDA stood at $-11,454,000, revealing a cost structure where operating expenses and research expenditures far exceed any revenue generation. Free cash flow for the period was recorded at $-11,966,500, indicating that the company is currently burning cash to fund its operations and development pipeline without generating sufficient liquidity from its business activities. The gross margin is reported at -45.5%, the operating margin is -14057.1%, and the profit margin is 0.0%, levels that collectively suggest the company is in a heavy investment phase where costs are not yet covered by sales. On the balance sheet, the company holds $3.05M in cash against $4.90M in debt, and with a debt-to-equity ratio listed as N/A, the firm appears to be leveraged given that its cash reserves are insufficient to fully cover its outstanding liabilities. The current ratio is 0.53, a figure that indicates the company faces potential challenges in meeting its short-term obligations with its existing liquid assets. Furthermore, the return on equity is N/A and the return on assets is -101.3%, metrics that reveal management has not yet generated positive returns on the capital invested in the company's operations or assets.

估值评估

The trailing P/E ratio is N/A while the forward P/E is -0.12, a disparity that implies earnings are currently negative and market expectations for future profitability remain highly uncertain or dependent on future revenue milestones. The price to book ratio is -0.16, a negative figure that indicates the market is not valuing the company's assets at a premium over their book value but rather reflects the severe financial distress and lack of retained earnings. Additional valuation metrics include a price to sales ratio of 47.96 and an EV/EBITDA of -0.53, suggesting that despite minimal sales, the market assigns a specific multiple to the entity, though the negative EV/EBITDA confirms that enterprise value is currently negative relative to earnings. Price metrics show a 52-week high of $19.74 and a 52-week low of $0.51, meaning the current trading price sits within a highly volatile range that spans more than thirty-seven times between its peak and trough. The beta is 1.36, which explains that the stock's price volatility is significantly higher than the broader market, moving 36% more aggressively than the average stock during periods of market fluctuation.

Growth & Income

Revenue growth year-over-year is -53.3% and earnings growth year-over-year is N/A, indicating that the company is experiencing a contraction in sales which is a primary driver of its financial performance rather than an acceleration in profitability. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that any available earnings or capital are theoretically reinvested into growth initiatives or used to service debt rather than distributed to shareholders. Since the company has no earnings to distribute, the reinvestment profile is entirely dependent on cash flow generation or external financing to sustain its immuno-pharma research programs. The overall growth and income profile for AIM ImmunoTech Inc. is characterized by negative revenue momentum, a complete absence of dividend income, and a reliance on capital markets to fund operations in the absence of positive cash flow generation.